Superparamagnetic nanoparticles as potential drug delivery systems for the treatment of Duchenne muscular dystrophy

Autor(es)

Schumacher, Maria L. ; Britos, Tatiane N. ; Fonseca, Fernando L. A. ; Ferreira, Fabio F. ; Feder, David ; Fratini, Paula ; Petri, Giuliana ; Haddad, Paula S.

• Tipo de documento: Artigo Científico
• Fonte: NANOSCALE; v. 17, n. 7, p. 16-pg., 2024-12-19.

Resumo

This study aims to use superparamagnetic iron oxide nanoparticles (SPIONs), specifically magnetite (Fe3O4), to deliver deflazacort (DFZ) and ibuprofen (IBU) to Duchenne muscular dystrophy-affected (DMD) mouse muscles using an external magnetic field. The SPIONs are synthesized by the co-precipitation method, and their surfaces are functionalized with l-cysteine to anchor the drugs, considering that the cysteine on the surface of the SPIONs in the solid state dimerizes to form the cystine molecule, creating the Fe3O4-(Cys)2-DFZ and Fe3O4-(Cys)2-IBU systems for in vivo tests. The Fe3O4 nanoparticles (NPs) were characterized by Fourier transform infrared spectroscopy (FTIR), Raman spectroscopy, powder X-ray diffraction (PXRD), transmission electron microscopy (TEM), dynamic light scattering (DLS), and magnetic measurements. The results show that the SPIONs have an average crystallite size of about 8 nm in the solid state and a hydrodynamic size of about 120 nm, which is suitable for biological applications in aqueous dispersion. The nanoparticles exhibit superparamagnetic behavior at room temperature and spherical-close morphology. In addition, vibrational modes characteristic of the functional groups of the molecules anchored to the surface of the SPIONs are identified. Data from blood tests of mdx mice after seven consecutive days of treatment with nanoparticles confirm the non-toxic nature of the system and show an improvement in DMD, with normal levels of liver and kidney enzymes and a decrease in creatine kinase protein. (AU)

• Processo FAPESP: 22/03647-4 - Nanopartículas de óxido de ferro e ouro aplicadas como carreadores de fármacos em biomedicina
• Beneficiário: Paula Silvia Haddad Ferreira
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 23/01502-1 - Síntese, caracterização e estudo de solubilidade de novas formas cristalinas de agentes neoplásicos
• Beneficiário: Fabio Furlan Ferreira
• Modalidade de apoio: Auxílio à Pesquisa - Regular